Breast cancer (13.7%) is the most often reported cancer worldwide, followed by colorectal cancer (11%). Because these patients’ immune systems are severely impaired, present chemotherapies for these two main tumours frequently result in secondary problems such as infections by bacteria, fungus, and viruses. For the treatment of breast cancer, a variety of cytotoxic medications are utilised, includ­ing doxorubicin, cisplatin, and bleomycin; nevertheless, they all have downsides and are ineffective. Nanomedicine is concerned with the development of innovative therapeutic and diagnostic modalities for human use using precision-engineered nanoparticles. Nanotechnology and medicine have merged to create new therapeutic and pharmacological possibilities. Nanoparticles could be used to target and treat cancerous cells as anticancer nanomedicines. The NPs could be used as antiangiogenic, anticancer, antipermeability, and antiproliferative molecular probes. AgNPs have been claimed to have the highest degree of commercialization among nanoparticles, and have gained a reputation in sectors such as medi­cine and materials research. AgNPs have unique features that enable these nanomedicines to successfully manage a variety of pathological diseases. AgNPs are effective against hepatitis B, respiratory syncytial illness, herpes simplex infection type 1 and monkey pox infection due to their antiviral characteristics (Khan et al., 2021).